Radionuclide therapy

We have substantial experience in performing studies with targeted radionuclide therapy in oncology. Our capabilities include testing of alpha- as well as beta-emitting ligands in subcutaneous, orthotropic or metastatic cancer models.

We facilitate clinical translation into Phase I studies including clinical trial design and execution in collaboration with our clinical partners.

Capabilities:

Approval of handling alpha- and beta-emitters, e.g. 177Lu, 131I, 227Th

Targeted radionuclide therapy in subcutaneous and orthotopic PDX models

Targeted radionuclide therapy in metastatic models

Custom radiolabeling of small molecules, peptides, proteins and antibodies

Contact Person

Carsten H. Nielsen, PhD

Co-founder, CEO

Contact